61 results about "Peripheral Artery Diseases" patented technology

A system leverages a multimodal model to predict peripheral arterial disease (PAD) risk. The system provides a dynamic questionnaire leveraging a language model to generate questions in response to user input. From the dynamic questionnaire, the system identifies user-specific risk factor(s) for PAD. The system also receives sensor data recorded by health sensor(s) including biometric signals of the user. The system applies a sensor classification model to the sensor data to output clinical data associated with a health state of the user. The system applies a multimodal PAD risk prediction model to the identified user-specific risk factors and the clinical data to output a PAD risk prediction indicating whether the user is at risk for PAD. Based on the outputs, the system generates and transmits one or more personalized recommendations for the user for treating or mitigating PAD risk and / or control instructions for controlling operation of the health sensor(s) and / or the medical device(s).

The invention provides a peripheral artery disease patient rehabilitation management system based on a whole process, and relates to the technical field of peripheral artery disease patient rehabilitation management. The system comprises a patient screening and risk grading module, a rehabilitation evaluation module, an exercise prescription generation and dynamic adjustment module, an intelligent propaganda and education content pushing module and a quality control closed-loop management module. PAD patients are accurately screened through a medical data interface and an NLP technology, and the risk levels of the patients are dynamically evaluated in combination with an intelligent risk grading system; generating a personalized exercise prescription according to the evaluation report, complication and biological monitoring data, and guaranteeing the exercise safety through a dynamic threshold model and collaborative early warning; dynamic matching and timeliness pushing of propaganda and education contents are realized by using an improved KL divergence algorithm; and full-process quality closed-loop management is realized through the quality control closed-loop management module. The precision and safety of rehabilitation management of the PAD patient can be improved, medical resource configuration is optimized, and rehabilitation practice driven by full-process data is assisted.

The invention discloses a human body peripheral blood vessel photoacoustic three-dimensional imaging device and an imaging method thereof, and belongs to the field of blood vessel imaging. Through high resolution and functional monitoring capability of photoacoustic imaging, detailed blood vessel structure and blood flow dynamic information are provided, and early recognition and treatment effect evaluation of common lesions such as diabetic foot and peripheral artery diseases are promoted; meanwhile, a mechanical system is adopted, so that the detection front end with relatively high quality can be borne, and stable operation is realized, and a relatively good photoacoustic imaging result is obtained; the system has a highly stable accurate scanning imaging mode, and is convenient for multiple imaging modes of clinical application; through the arrangement of the imaging water tank and the lifting structure of the imaging water tank, switching of imaging modes in a limited space can be ensured, so that the device can be suitable for the layout of a portal type three-dimensional moving device. The system is expected to promote the portability of equipment, reduce the research and development cost of the equipment, be widely applied to clinical practice and community medical treatment, and improve the disease management level.

The invention provides an application of a super enhancer inhibitor JQ-1 in preparation of peripheral artery disease related drugs, relates to the technical field of biomedicine, and discloses a core effect of the super enhancer inhibitor JQ-1 in peripheral artery disease ischemia repair. The traditional Chinese medicine composition can significantly accelerate blood flow recovery of ischemic limbs, up-regulate mRNA and protein expression of a vascular marker CD31 in gastrocnemius muscle tissues, effectively increase vascular density and promote angiogenesis. Aiming at the defects of the existing treatment means in the aspect of ischemic tissue angiogenesis, the application provides a brand new molecular targeted treatment scheme for high-risk groups such as patients with diabetes-related peripheral artery diseases, and can significantly reduce the risk of lower limb amputation and the incidence rate of related cardiovascular adverse events such as coronary heart disease and stroke; the technical blank of specific targeted therapy of peripheral artery diseases is filled, a solid scientific basis and a key direction are provided for research and development of novel drugs, and the specific targeted therapy method has extremely high clinical application value and wide research and development prospects.

Exemplary embodiments of the present disclosure apparatus and methods for enhancing the steerability of catheters, including for example those used in peripheral artery disease PAD interventions. Exemplary embodiments include a permanent magnet coupled to an end of a segmented tubular member, an electromagnet, and a controller configured to control a magnetic force exerted by the electromagnet on the permanent magnet. Exemplary embodiments further comprise systems and methods for detecting the location of a magnetic element via magnetic sensors.

The present invention relates to a weighing scale (100) for monitoring biometric data of a user (180). The weighing scale (100) comprises a first set and a second set of multiple electrodes disposed on one or more handles (120) for making contact with a first hand and a second hand of the user (180). The weighing scale (100) further comprises a base (140) for supporting the user (180) and determining a weight of the user (180). A first portion of a top surface of the base (140) comprises a third set of multiple electrodes for making contact with a first foot of the user (180) and a second portion of the top surface of the base (140) comprises a fourth set of multiple electrodes for making contact with a second foot of the user (180). The weighing scale (100) further comprises processing circuitry for obtaining a plurality of biometric signals and determining a pulse wave velocity (PWV) of the first hand and the second hand and the first foot and the second foot of the user (180) based on the plurality of biometric signals to estimate a peripheral arterial disease (PAD) risk of the user (180).

The present invention relates to a novel route for preparing oxopyridine compounds shown in formula (I) and their key intermediates. The novel route provided by the present invention can greatly reduce the generation of isomeric impurities, improve the chiral selectivity of the reaction and the N / O-alkylation selectivity, increase the yield, eliminate the need for further purification of the crude product, reduce the cost, shorten the production cycle, save energy and protect the environment, and is suitable for use in the preparation of drugs for treating and / or preventing diseases related to the FXIa receptor, especially providing a new idea for the preparation of drugs for treating and / or preventing cerebrovascular arterial diseases and / or peripheral arterial diseases.

This application relates to the field of biomedical engineering technology. This application discloses a method, device, terminal device and storage medium for dual-foot sole video evaluation based on plantar perfusion imaging, which can improve the accuracy of evaluation results, simplify the measurement process and enhance the patient experience. The method includes obtaining a dual-foot sole video; obtaining a plurality of left plantar rPPG signals and a plurality of right plantar rPPG signals based on the dual-foot sole video; drawing a plurality of dual-foot sole perfusion maps based on the plurality of left plantar rPPG signals and the plurality of right plantar rPPG signals; generating a target image based on the plurality of dual-foot sole perfusion maps; extracting the average value, standard deviation, maximum value and minimum value of the blood perfusion index ratio from the target image and inputting them into a classifier for evaluation processing to obtain an evaluation result, and medical staff refer to the evaluation result to diagnose peripheral artery disease and its severity.

The subject invention pertains to a novel method for treating Peripheral Arterial Disease (PAD) by leveraging the angiogenic potential oftype 2 cytokines IL-4 and IL-13 to enhance the efficacy of induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) and induced endothelial cells derived from fibroblasts (iECs). This present invention aims at enhancing the muscle regeneration and revascularization for obese and diabetes individuals.

The invention discloses a peripheral arteriosclerosis blood circulation anomaly detection system based on near infrared spectroscopy (NIRS) and a detection method thereof, the peripheral arteriosclerosis blood circulation anomaly detection system based on NIRS not only improves the detection efficiency and accuracy of peripheral arteriosclerosis diseases through technical innovation, but also has wide applicability and practicability, and is suitable for popularization and application. Good market prospects and social values are realized.

The present invention generally relates to pharmaceutical compositions, methods, and devices / systems for treating vascular diseases. More particularly, the present invention relates to medical methods, devices, and kits for delivering drugs to peripheral vascular tissue to treat neointimal growth. More specifically, the present invention described herein is intended to overcome the drawbacks of existing treatments for peripheral artery disease (PAD). The devices and methods of the present invention are for reducing one or more pathological conditions; reducing treatment complications in the treated patient population, reducing the target lesion revascularization (TLR) rate; and reducing the patient population that requires any type of leg amputation, particularly for patients with PAD associated with infrapopliteal (tibial) arteries, such as patients with clinical indications for treatment below the knee (e.g., claudication and / or critical limb ischemia (CLI)) for treatment below the knee, and patients with complex pathologies are specifically contemplated.

The present invention discloses a compound represented by formula (I), its stereoisomers, or a pharmaceutically acceptable salt. The present invention also provides the use of the compound, its stereoisomers or a pharmaceutically acceptable salt in the preparation of a medicament for treating and / or preventing diseases related to the FXIa receptor, especially in the preparation of a medicament for treating and / or preventing cerebrovascular arterial diseases and / or peripheral arterial diseases, with better efficacy and higher safety.

The present invention relates to a novel route for preparing oxopyridine compounds represented by formula (I) and their key intermediates. This novel route significantly reduces the generation of isomeric impurities, improves reaction chiral selectivity and N / O-alkylation selectivity, and enhances yield. It is particularly effective for chemical resolution of novel structures in which R1 is a non-hydrogen group. The resulting crude product eliminates the need for costly chiral purification (SFC), reducing costs, shortening production cycles, and being energy-efficient and environmentally friendly. The novel route is suitable for preparing drugs for treating and / or preventing diseases associated with the FXIa receptor, and in particular, provides a novel approach for preparing drugs for treating and / or preventing cerebrovascular arterial disease and / or peripheral arterial disease. #imgabs0#

A siRNA for inhibiting LPA gene expression, and a modifier and the use thereof, belonging to the field of biomedicine. Provided are a double-stranded RNA molecule targeting an LPA gene, and a modifier thereof. Both in vivo and in vitro experiments show that the provided double-stranded RNA molecule can effectively inhibit LPA gene expression, and can be used for preventing and / or treating Lp(a)-related diseases, such as thrombosis, atherosclerotic thrombosis, coronary artery disease, ischemic strokes, aortic valve stenosis, heart failure, atrial fibrillation, and peripheral artery disease.

The present invention discloses a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention also provides the use of the compound, its stereoisomer or pharmaceutically acceptable salt in the preparation of a drug for treating and / or preventing diseases associated with FXIa receptors, especially in the preparation of a drug for treating and / or preventing cerebrovascular arterial disease and / or peripheral arterial disease, with significant therapeutic effect.

The present invention provides a closed loop generation and / or infusion system comprising a radionuclide generator, an activity detector, a controller, a dose calibrator, a pump, eluant source and an automated elution system controlled by software and hardware for generation and infusion of a radionuclide for administering a dose of generated radionuclide into a subject for diagnosing a peripheral arterial disease in a subject suffering from or suspected of suffering from peripheral arterial disease and / or metabolic disease via Positron Emitting Tomography (PET) or Single-photon emission computed tomography (SPECT) imaging technologies. More particularly, the present invention provides methods of determining whether a subject is suffering or at a risk of developing a peripheral arterial disease by performing quantitative assessment of blood flow in lower extremities or limbs of the subject; wherein the quantitative assessment is performed by analyzing one or more images and providing a severity score; and wherein the analysis of the one or more images is performed by using an automated system.

The present invention discloses a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention also provides the use of the compound, its stereoisomer or pharmaceutically acceptable salt in the preparation of a drug for treating and / or preventing diseases associated with FXIa receptors, especially in the preparation of a drug for treating and / or preventing cerebrovascular arterial disease and / or peripheral arterial disease, with significant efficacy.

The present invention discloses a compound represented by formula (I), its stereoisomers, or a pharmaceutically acceptable salt. The present invention also provides the use of the compound, its stereoisomers or a pharmaceutically acceptable salt in the preparation of a medicament for treating and / or preventing diseases related to the FⅪa receptor, especially in the preparation of a medicament for treating and / or preventing cerebrovascular arterial diseases and / or peripheral arterial diseases, and the drug effect is remarkable.

The present invention provides a compound having a PDHK inhibitory activity and useful for the treatment or prophylaxis of diabetes (type 1 diabetes, type 2 diabetes etc.), insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactacidemia, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract etc.), cardiac failure (acute cardiac failure, chronic cardiac failure), cardiomyopathy, myocardial ischemia, myocardial infarction, angina pectoris, dyslipidemia, atherosclerosis, peripheral arterial disease, intermittent claudication, chronic obstructive pulmonary disease, brain ischemia, cerebral apoplexy, mitochondrial disease, mitochondrial encephalomyopathy, cancer, pulmonary hypertension or Alzheimer disease. The present invention relates to a compound of the formula [I-a] or the formula [II], or a pharmaceutically acceptable salt thereof:wherein each symbol means the same as that described in the specification.

Methods and systems are disclosed for using medical imaging data to diagnose peripheral arterial disease. In a method, a plurality of artificial intelligence based neural network models are trained on medical imaging data of a large population of anonymous patients after labeling and structuring the data for training and testing purposes. Medical imaging data of a known patient is then processed by the plurality of pre-trained artificial intelligence based neural network models to diagnose peripheral arterial disease. A rule-based algorithm integrates the predictions made by the pre-trained neural network models. An inference engine analyzes the integrated predictions data for the known patient, detects any anomalies in the pixel intensities present in each medical image, and performs volumetric calculations. A report generation engine generates medical reports for the known patient. A visualization tool enables a clinician to display and view the results of the diagnoses superimposed on medical images.

Disclosed herein is a further medical use of semaglutide, namely semaglutide in the treatment of intermittent claudication in a human subject with diabetes and peripheral arterial disease. Semaglutide is shown to have a positive impact on symptoms of intermittent claudication and therefore the functional limb capacity and quality of life of patients with type 2 diabetes and peripheral arterial disease.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The present invention provides a method for constructing a rat model simulating the clinical characteristics of peripheral arterial disease, comprising the following steps: Step 1: A unilateral femoral artery of a diabetic rat is ligated with an Ameroid constrictor ring, and the rat is raised for a period of time; Step 2: The femoral artery of the rat surviving after being raised in Step 1 is ligated. In Step 1 and Step 2, the ligation of the Ameroid constrictor ring and the femoral artery ligation are both located on the same side femoral artery of the rat. The present invention establishes a chronic limb ischemia animal model conforming to the clinical characteristics of peripheral arterial disease. The present invention intends to induce type 2 diabetes in rats by feeding them with a high-fat and high-sugar diet, use an Ameroid constrictor ring on the femoral artery to cause progressive limb ischemia, and then ligate the femoral artery to cause vascular occlusion to simulate critical limb ischemia. The "staged" chronic limb ischemia in diabetic rats provides a suitable animal model for the basic research of peripheral arterial disease.

The application discloses a kind of human peripheral blood vessel photoacoustic three-dimensional imaging device and imaging method thereof, belong to blood vessel imaging field.The application provides detailed blood vessel structure and blood flow dynamic information by high resolution and functional monitoring ability of photoacoustic imaging, promote early identification and treatment effect evaluation to common pathological changes such as diabetic foot and peripheral arterial disease;Meanwhile, the application adopts mechanical system, and the detection front end of higher quality can be carried and stably operated, to obtain better photoacoustic imaging result;The application has highly stable precision scanning imaging mode, and various imaging modes are convenient for clinical application;Through the arrangement of imaging tank and its lifting structure, it is ensured that the switching of imaging mode can be applied in limited space, so as to be suitable for gantry type three-dimensional mobile device layout.The application is expected to promote the portability of equipment, reduce equipment development cost, be widely applied in clinical practice and community medical treatment, and improve disease management level.

Disclosed are methods and systems for determining an extent of PAD. The method may include a step of comparing a pre-PAD treatment oxygenation readings by obtaining a supine reading and limb raise reading to post-PAD treatment oxygenation readings of the limb or the portion thereof using a non-contact NIRS camera of a limb or a portion thereof, distal to a PAD treatment site using a supine reading and limb raise reading to post-PAD treatment oxygenation readings of the limb or the portion thereof using a second supine reading and a second limb raise reading. An indication may be presented of an improvement or a non-improvement in PAD in the limb based on a difference in oxygenation from pre-PAD treatment readings to post-PAD treatment oxygenation readings of the limb.

Disclosed herein is a further medical use of semaglutide, namely semaglutide in the treatment of intermittent claudication in a human subject with diabetes and peripheral arterial disease. Semaglutide is shown to have a positive impact on symptoms of intermittent claudication and therefore the functional limb capacity and quality of life of patients with type 2 diabetes and peripheral arterial disease.

The present invention discloses a compound represented by formula (I), a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The present invention also provides the use of the compound, its stereoisomer or pharmaceutically acceptable salt in the preparation of a drug for treating and / or preventing diseases associated with FXIa receptors, especially in the preparation of a drug for treating and / or preventing cerebrovascular arterial disease and / or peripheral arterial disease.

The present disclosure provides pharmaceutical compositions comprising an anticoagulant and pyruvic acid. Also provided are dosage forms comprising the pharmaceutical composition and methods for treating a thromboembolic disorder in a patient in need thereof, reducing the reoccurrence of a deep vein thrombosis or a pulmonary embolism in a patient in need thereof, preventing a venous thromboembolism (VTE) in an acutely ill patient, reducing the risk of a major cardiovascular event in a patient with coronary artery disease in a patient in need thereof, method for reducing the risk of a major thrombotic vascular event in a patient with peripheral artery disease (PAD), treating VTE or reducing the risk of reoccurrence of VTE in a pediatric patient in need thereof, thromboprophylaxis in a patient with congenital heart disease after a Fontan procedure, treating atherosclerosis, myocardial infarct, pulmonary embolism or deep venous thrombosis in a patient in need thereof, or preventing one or more thromboembolic or hemorrhagic events in a patient with atrial fibrillation by comprising administering the pharmaceutical composition or transdermal patch described herein to the patient.

RNA interference (RNAi) agents for inhibiting the expression of Factor XI (FXI) are provided, as are pharmaceutical compositions comprising one or more FXI RNAi agents together with one or more excipients capable of delivering the RNAi agent(s) to a liver cell in vivo. Delivery of the FXI RNAi agent(s) to liver cells in vivo provides for inhibition of FXI gene expression and can provide for treatment of myocardial infarction, atrial fibrillation (AFib), deep vein thrombosis, pulmonary embolism, ischemic stroke, transient ischemic attack, retinal artery occlusion, mesenteric ischemia, renal vein thrombosis, cerebral venous sinus thrombosis, venous thromboembolism due to deep vein thrombosis, and peripheral artery disease, as well as diseases and disorders associated with angioedema, thrombosis, and / or coagulation.

The present application relates to a DNA drug, a gene targeting delivery system and its application in the treatment of lower extremity peripheral arterial disease. Specifically, the present application relates to a microcrystalline nanocarbon targeted drug delivery system and a plasmid containing human interleukin-4 gene loaded thereon. The delivery system comprises a matrix microcrystalline nanocarbon, and folate, polyethyleneimine and polyethylene glycol modified on the surface thereof. The matrix microcrystalline nanocarbon has a size of 5-20 nanometers, a crystallinity of >80%, a rich mesoporous structure, a high specific surface area and good biocompatibility. The present application also provides a preparation method of the system, which comprises the steps of synthesizing a matrix by pulse modulation radio frequency plasma enhanced chemical vapor deposition, surface functionalization modification and plasmid loading. After injection into the lower extremity muscle, the system can actively target the macrophages in the ischemic site, realize long-term expression of the IL-4 gene at the lesion site. It can effectively promote stable, mature functional angiogenesis by inducing macrophages to polarize to the repair M2 phenotype and regulating the OSM / GSNOR / ENG signal axis, thereby improving limb ischemia. The present application has important application value in the field of gene therapy for ischemic diseases, especially peripheral arterial disease and severe limb ischemia.